Endoscopic Probe Disinfection Market: as FDA 2024 supplemental duodenoscope reprocessing guidance reinforces validated HLD and sterilization requirements compelling hospital investment in traceable automated systems, STERIS Healthcare segment USD 3.61 Billion FY2024 at 13% constant currency organic growth anchors the HLD consumable and AER disinfection market, so HOYA acquisition of PLASMABIOTICS in December 2024 adds plasma-based non-aldehyde reprocessing technology challenging established glutaraldehyde HLD chemistries, and Iran-US sanctions disruption to glutaraldehyde and OPA precursor supply chains maintains elevated input costs for European and Asian disinfection product manufacturers.

The global endoscopic probe disinfection market size was USD 2.42 Billion in 2025 and is expected to register a revenue CAGR of 6.8% during the forecast period. Market revenue growth is driven by factors such as expanding endoscopic procedure volumes generating non-discretionary per-procedure HLD consumable and AER utilisation demand, active acquisition-driven portfolio consolidation bringing non-aldehyde plasma-based reprocessing technologies into major vendor portfolios, and as well as EU healthcare-associated infection surveillance data attributing 3.5 million HAIs annually to reusable device reprocessing lapses creating regulatory pressure for validated automated disinfection systems with digital scope traceability. The first driving factor is the FDA 2024 supplemental guidance on duodenoscope reprocessing with elevator channels, reinforcing validated HLD and sterilization protocol requirements and compelling US hospital and ambulatory surgery centre investment in automated endoscope reprocessors that provide documented, traceable reprocessing cycles with scope-level compliance documentation, generating AER capital procurement and associated HLD chemistry recurring consumable revenue at facilities upgrading from standard flexible endoscope HLD to duodenoscope-specific validated reprocessing infrastructure. The second driving factor is the HOYA Corporation acquisition of the remaining PLASMABIOTICS shares in December 2024, integrating PlasmaTYPHOON and AquaTYPHOON plasma-based non-aldehyde flexible endoscope reprocessing enhancement systems into the HOYA PENTAX Medical portfolio, combined with the Ecolab Healthcare ANZ acquisition of TCS Medical in September 2024 expanding EndoSelect endoscopy consumable distribution across Australia and New Zealand, confirming active acquisition-driven portfolio expansion beyond established glutaraldehyde and OPA HLD chemistries toward non-aldehyde plasma-based and peracetic acid reprocessing technologies. The third driving factor is the EU healthcare-associated infection surveillance data attributing more than 3.5 million HAIs annually across EU member states to reusable device reprocessing lapses, creating institutional pressure on hospital infection control committees toward digital scope traceability and validated automated disinfection systems that reduce HAI liability exposure and satisfy European decontamination guideline requirements. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way validated reprocessing chemistry lock-in to compatible AER platforms compounds recurring consumable revenue per installed instrument base over time, which allows HLD chemistry manufacturers that supply validated consumables to specific AER platforms to generate durable per-procedure recurring revenue without requiring active commercial selling at each reprocessing episode. Once a hospital sterile processing department installs an AER validated for a specific HLD chemistry formulation, the reprocessing protocol documentation requires use of the validated chemistry to maintain cycle efficacy certification, making alternative chemistry substitution a revalidation event that requires independent testing and regulatory submission, creating a multi-year commercial lock-in that sustains per-procedure HLD consumable revenue for the validated chemistry supplier. As a result, demand and revenue share are concentrating around AER manufacturers and HLD chemistry suppliers that hold the deepest validated compatibility portfolios across the broadest flexible endoscope model ranges, and the forecast tilts toward these validated-platform combinations rather than standalone chemistry or standalone AER competitors. For instance, in May 2025, Olympus launched the ScopeLocker Air endoscope drying cabinet to improve infection prevention through optimal forced-air drying and hygienic storage following completed reprocessing cycles, one of several commercial and regulatory events reshaping the competitive landscape in the 12 months to Q2 2026. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the dual regulatory pressure from US FDA guidance on duodenoscope reprocessing and EU healthcare-associated infection surveillance data, both compelling hospital infection control committees to invest in validated automated endoscope reprocessing systems with scope-level electronic compliance documentation that can satisfy both jurisdictional regulatory frameworks. Regulatory-driven AER adoption works commercially because the FDA 2024 supplemental guidance on duodenoscope reprocessing reinforces validated HLD and sterilization protocol requirements, compelling US hospitals and ASCs to invest in AER systems providing documented, traceable reprocessing cycles with cycle parameters, chemical concentration, water quality measurements, and scope serial number logged per disinfection run, converting the FDA guidance into capital procurement decisions at the approximately 4,000 US hospitals and ASCs using duodenoscopes. EU surveillance data attributing more than 3.5 million HAIs annually to reusable device reprocessing lapses across EU member states drives infection control policy pressure at European hospital procurement committees toward validated automated systems with RFID scope tracking and cloud-connected compliance dashboards. More than 20 million gastrointestinal examinations are performed annually in the United States alone per 2024 Scientific Reports meta-analysis, each generating demand for a complete validated reprocessing cycle with HLD chemical consumption. STERIS Healthcare segment constant currency organic growth of 13% FY2024 driven primarily by the United States per CEO Dan Carestio Q4 FY2024 earnings call reflects the commercial benefit of regulatory-driven AER and HLD consumable demand. These are some of the key factors driving revenue growth of the market.

The second driver is the accelerating consolidation of endoscope disinfection portfolio capabilities through acquisitions bringing non-aldehyde reprocessing technologies into established infection prevention company portfolios, reflecting the commercial strategy of reducing occupational health exposure risks and environmental disposal costs associated with aldehyde-based HLD chemistries. Non-aldehyde disinfection chemistry works commercially because glutaraldehyde-based HLD programmes require hazardous chemical handling, OSHA vapour exposure limits and mandatory ventilation infrastructure, mandatory occupational health monitoring for staff sensitisation, and regulated hazardous waste disposal, all adding indirect costs to aldehyde HLD programmes that plasma-based or peracetic acid chemistries generating active biocides from water and electricity or pharmaceutical-grade reagents can eliminate. HOYA Corporation acquired the remaining PLASMABIOTICS shares in December 2024, becoming the sole owner of the France-based company known for PlasmaTYPHOON and AquaTYPHOON plasma-based non-aldehyde endoscope reprocessing systems, integrating plasma chemistry into the HOYA PENTAX Medical portfolio. Ecolab Healthcare ANZ acquired TCS Medical in September 2024, expanding EndoSelect endoscopy consumable distribution across Australia and New Zealand with ISO 13485 certified local assembly capabilities. STERIS RAPICIDE OPA/28 demonstrates the portfolio breadth market-leading disinfection companies maintain across multiple HLD platforms to serve different hospital protocol preferences. These are some of the key factors driving revenue growth of the market.

HOYA PLASMABIOTICS December 2024 acquisition integrates a plasma-based chemistry that generates active biocides from water and electricity without hazardous chemical handling. The occupational health burden of glutaraldehyde in sterile processing departments is real: OSHA exposure limits, staff sensitisation rates, mandatory ventilation requirements, and hazardous waste disposal costs add significant indirect costs to aldehyde HLD programmes. If PlasmaTYPHOON achieves equivalent clinical validation to glutaraldehyde HLD in flexible scope reprocessing, it could convert sterile processing department procurement toward plasma-based chemistries over a five to seven year adoption cycle.

The third driver is the expansion of the endoscopic probe disinfection market scope beyond HLD chemistry and AER hardware into drying, storage, and digital compliance tracking as hospital infection control programmes implement complete chain-of-custody documentation across all post-procedure endoscope handling steps. Digital compliance ecosystem expansion works commercially because Joint Commission 2024 HLD cycle tracking mandates require electronic documentation not just of the AER reprocessing cycle but of the scope's entire post-procedure handling chain including drying, storage, and retrieval, creating demand for integrated drying and storage systems that connect with AER electronic records in a continuous compliance audit trail. Olympus launched the ScopeLocker Air endoscope drying cabinet in May 2025, designed to improve infection prevention through optimal forced-air drying and hygienic storage of endoscopes following completed high-level disinfection or sterilization cycles, addressing the residual moisture contamination risk period between reprocessing completion and scope deployment for the next patient procedure. STERIS's December 2024 Integrated Medical Systems acquisition adding drying cabinets and storage to its AER portfolio similarly reflects the industry move toward complete scope lifecycle compliance coverage. Digital compliance tracking software at approximately 5% of 2025 market revenue is expected to register the fastest growth rate in the global endoscopic probe disinfection market over the forecast period, driven by hospital demand for cloud-connected compliance dashboards integrating AER cycle data, scope RFID tracking, drying cabinet sensor data, and electronic sterile processing department records. These are some of the key factors driving revenue growth of the market.

However, the endoscopic probe disinfection market faces adoption constraints from single-use endoscope growth and Iran-US sanctions chemical supply chain disruption. Because single-use endoscope adoption is growing at approximately 12.5% annually in bronchoscopy and ureteroscopy driven by Ambu and Olympus single-use programmes, each converted department eliminates its per-procedure HLD consumable demand, creating a structural headwind for chemistry recurring revenue in the highest-infection-risk endoscope categories where single-use conversion is occurring fastest, reducing the duodenoscope and bronchoscope HLD addressable market at facilities converting to single-use formats. Iran-US sanctions disruption to glutaraldehyde and OPA specialty chemical precursor supply chains through Strait of Hormuz logistics corridors has maintained elevated HLD chemical input costs above pre-2022 baseline levels for European and Asian endoscope disinfection product manufacturers through 2026, constraining gross margin improvement on aldehyde chemistry products at a time when OPA and glutaraldehyde alternatives to premium peracetic acid and plasma chemistries are under cost pressure from both input supply disruption and the commercial positioning of non-aldehyde alternatives. Transition to sterilization-as-a-service models including Olympus On-Demand reduces per-hospital HLD consumable purchasing volume at converting accounts, substituting a managed per-procedure service revenue model for the traditional HLD chemistry consumable sales model. These factors substantially limit endoscopic probe disinfection market growth over the forecast period.

Based on product, the global endoscopic probe disinfection market is segmented into high-level disinfectants and test strips, automated endoscope reprocessors, detergents and enzymatic cleaners, drying and storage systems, and digital compliance tracking software. High-level disinfectants and test strips hold the largest revenue share at approximately 33%, anchored by STERIS RAPICIDE and RAPICIDE OPA/28 systems validated for both manual and automated reprocessing, Ecolab Healthcare OPA and peracetic acid HLD products, and Metrex MetriCide OPA 28 for flexible endoscopes. Automated endoscope reprocessors are expected to register a rapid revenue growth rate in the global endoscopic probe disinfection market over the forecast period, driven by FDA and Joint Commission regulation compelling hospital adoption of traceable automated systems with integrated digital logging and scope-level RFID identification.

Based on endoscope type, the global endoscopic probe disinfection market is segmented into flexible GI endoscopes, flexible bronchoscopes and cystoscopes, and ultrasound probes and TEE probes. Flexible GI endoscopes including colonoscopes, gastroscopes, and duodenoscopes hold the largest revenue share, reflecting the highest per-facility endoscope inventory count and daily reprocessing cycle volume at hospital gastroenterology and endoscopy suite departments. Flexible bronchoscopes and cystoscopes are expected to register a declining share over the forecast period as single-use conversion progresses in pulmonology and urology departments converting from reusable to disposable scope formats, while core colonoscope and gastroscope GI endoscopy reprocessing volumes remain structurally secure from single-use conversion given cost economics.

Based on regional analysis, the endoscopic probe disinfection market in North America accounted for largest revenue share in 2025 at approximately 40% of global revenue. STERIS Healthcare constant currency organic growth of 13% FY2024 driven primarily by the United States per CEO Dan Carestio reflects strong procedural volume growth generating sustained HLD consumable and AER service revenue. The United States drives the regional position through FDA regulatory enforcement of validated duodenoscope reprocessing protocols, STERIS dominant AER and HLD consumable market position through the Cantel Medivators acquisition, and high per-facility flexible endoscope inventory at hospital gastroenterology, pulmonology, and urology departments generating non-discretionary per-procedure HLD consumable demand.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, the United Kingdom, and the Netherlands represent the four largest national endoscope disinfection markets within Europe. EU surveillance data attributing 3.5 million HAIs annually to reusable devices drives European hospital procurement toward validated automated systems with digital traceability. HOYA PLASMABIOTICS December 2024 integrates plasma-based endoscope reprocessing enhancement technology developed in France into the HOYA PENTAX Medical European portfolio. The ongoing Iran-US sanctions and associated Strait of Hormuz maritime disruption affect glutaraldehyde and OPA precursor supply chains, maintaining elevated HLD chemical input costs for European disinfection product manufacturers and contributing to European diagnostic reagent pricing stickiness through the 2026 to 2027 outlook period.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. Japan, China, India, and Australia represent the four largest national endoscope disinfection markets within the region. Olympus Australia opened Sapphire sterile scope facility in Melbourne in September 2024 under the Olympus On-Demand model, and Ecolab Healthcare ANZ acquired TCS Medical in September 2024 to expand EndoSelect endoscopy consumable distribution across Australia and New Zealand. Japan's JGES 2022 guideline specifying AER use as the preferred flexible endoscope reprocessing method sustains AER chemistry consumable pull-through revenue at Japan's estimated 14,800 GI endoscopy facilities.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national endoscope disinfection markets. The indirect effects of Iran-US sanctions on glutaraldehyde and OPA precursor chemical supply chains along South American trade lanes have maintained elevated HLD consumable import costs in Brazilian endoscopy department supply chains through 2026, constraining margin recovery on HLD chemistry products even as procedure volumes drive underlying consumable demand growth.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets. GCC hospital sterile services departments at new tertiary hospitals built under Saudi Vision 2030 healthcare capacity expansion programmes are procuring automated endoscope reprocessing systems and validated HLD chemistry programmes as part of international standard sterile processing infrastructure. King Faisal Specialist Hospital and Cleveland Clinic Abu Dhabi operate among the most advanced endoscopy reprocessing programmes in the MEA region.